Sironax, an emerging biotechnology company, announced on August 2 its completion of round-B financing, bringing the firm’s total fundraising to more than $300 million.
It raised a total of $200 million in this round, which was jointly led by YF Capital and Gaorong Capital. Existing investors included Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, and K2VC also participated. The new investors included MSA Capital, a wholly-owned subsidiary of Abu Dhabi Investment Authority (ADIA), CBC Group, Long River Investments, LSV Capital, Superstring Capital, and Future Innovation Fund.
Since its establishment in 2017, Sironax has built a diverse R&D pipeline that focuses on key pathogenic mechanisms of aging-related degenerative diseases, including cellular programmed death, neuroprotective pathways and neuroinflammation. The company currently undertakes several preclinical studies and has early clinical studies underway for two drug candidates: SIR0365 and SIR2446.
The proceeds from the recently concluded round will be used for the clinical development of receptor-interacting protein kinase 1 (RIPK1) inhibitors and to further expand its R&D scale and pipeline to develop drug candidates for aging-related degenerative diseases.
Dr. Ren Gang, CEO of Sironax, said: “We are very pleased to secure the support of top investors to make our vision of bringing transformative therapies to patients affected by degenerative diseases around the world a reality.”